[EN] TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS<br/>[FR] COMPOSÉS DE TÉTRAHYDROISOQUINOLÉINE UTILISÉS EN TANT QU'ACTIVATEURS DE NRF2
申请人:C4X DISCOVERY LTD
公开号:WO2021214472A1
公开(公告)日:2021-10-28
The present invention relates to compounds that are Nrf2 activators. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with Nrf2 activation.
The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Ectonucleotidase inhibitors and methods of use thereof
申请人:Calithera Biosciences, Inc.
公开号:US11078228B2
公开(公告)日:2021-08-03
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
本发明涉及新型杂环化合物及其药物制剂。本发明还涉及使用本发明的新型杂环化合物治疗或预防癌症的方法。
Substituted purines as TLR7 agonists
申请人:Primmune Therapeutics, Inc.
公开号:US11059824B2
公开(公告)日:2021-07-13
The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.